Overview
- 7 inspections across 6 sites are on record.
- 0 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2014-01-17.
At a glance
Inspections
7
Sites
6
Observations
0
Career since
May 2008
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Merck Sharp & Dohme LLC | 17 Jan 2014 | Biologics | On file |
| Omrix Biopharmaceuticals Ltd. | 19 May 2011 | On file | |
| OMRIX BIOPHARMACEUTICALS LTD | 19 May 2011 | On file | |
| Merck Sharp & Dohme LLC | 14 May 2010 | On file | |
| CSL Behring AG | 22 Jan 2009 | On file |
Sites inspected
Merck Sharp & Dohme LLCDurham, United States2 insp.
Omrix Biopharmaceuticals Ltd.Nes-Ziona, Israel1 insp.
OMRIX BIOPHARMACEUTICALS LTDRamat Gan, Israel1 insp.
CSL Behring AGBern, Switzerland1 insp.
Co-investigators
Investigators who share inspections with this person.
Randa Melhem3 shared
Jeremy L Wally1 shared
Chad R Burger1 shared
Robert D Tollefsen1 shared
Seneca D Toms1 shared
Nawab A Siddiqui1 shared
Joseph D Doleski1 shared
Joyce A Rockwell1 shared
Full investigator report
Get the verbatim findings behind Destry M Sillivan's inspection record
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site